Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGRP Hypersensitivity as a Predictor of Erenumab Response in Migraine
NCT04592952Phase 4Unknown
- Sponsor
- Dansk Hovedpinecenter
- Start
- Oct 2020
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of erenumab in migraine, sponsored by Dansk Hovedpinecenter. Status: unknown.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04592952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592952.